SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Filing Cabinet
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: EepOpp who started this subject5/31/2002 4:27:48 PM
From: EepOpp   of 15
 
ITMN-Actimmune-pulmonary fibrosis

Message 17517484

Positive plug for itmn in this week's Barron's:
Excerpt mentioning itmn:

"Sjostrom is partial to Intermune, whose stock trades for 28, giving it a market value of $850 million. It has about $8 a share in net cash. Intermune already markets a hepatitis drug, but Sjostrom is most excited about a yet-to-be-approved drug, Actimmune, which has many potential uses, including treatment of a usually fatal lung disease, pulmonary fibrosis. Annual sales eventually could total $1 billion."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News